InspireMD (NYSE:NSPR) Now Covered by StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Sunday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price on the stock.

InspireMD Price Performance

NYSE:NSPR opened at $2.98 on Friday. The firm has a market cap of $77.73 million, a price-to-earnings ratio of -3.97 and a beta of 1.00. The firm’s fifty day moving average price is $2.84 and its 200 day moving average price is $2.76. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.80.

Institutional Trading of InspireMD

Hedge funds have recently modified their holdings of the business. Affiance Financial LLC raised its position in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after acquiring an additional 5,376 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of InspireMD during the 4th quarter worth $27,000. Legato Capital Management LLC purchased a new position in shares of InspireMD in the 4th quarter valued at about $47,000. Schonfeld Strategic Advisors LLC lifted its stake in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares during the period. Finally, Northern Trust Corp boosted its holdings in InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after buying an additional 24,452 shares in the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.